Actively Recruiting
Echocardiography Guided TAVR (Echo TAVR)
Led by Pan Xiangbin · Updated on 2025-06-19
20
Participants Needed
1
Research Sites
45 weeks
Total Duration
On this page
AI-Summary
What this Trial Is About
Conventional transcatheter aortic valve replacement (TAVR) relies on fluoroscopic and contrast agents. However, in high-risk patients, exposure to ionizing radiation and contrast agents is contraindicated and undesirable. Echocardiography guidance TAVR can offer a feasible and safer strategy for TAVR.
CONDITIONS
Official Title
Echocardiography Guided TAVR (Echo TAVR)
Who Can Participate
Eligibility Criteria
You may qualify if you...
- Symptomatic severe aortic stenosis confirmed by echocardiography and Doppler with mean gradient ≥40 mmHg, peak aortic velocity ≥4 m/s, and aortic valve area ≤1 cm2 (or indexed AVA ≤0.6 cm2/m2)
- History of malignancy or high familial cancer risk, with refusal to undergo contrast- or radiation-guided procedures
- Chronic kidney disease with refusal to receive contrast agents or radiation exposure
You will not qualify if you...
- Need for hybrid procedures or additional interventions on other cardiac malformations
- Inoperable due to extremely high surgical risk or severe comorbid conditions
- Untreated significant coronary vascular disease that can be treated with revascularization
- Previous aortic valve replacement
AI-Screening
AI-Powered Screening
Complete this quick 3-step screening to check your eligibility
Trial Site Locations
Total: 1 location
1
Fuwai Hospital
Beijing, China, 100037
Actively Recruiting
Research Team
X
Xiangbin Pan, MD
CONTACT
F
Fengwen Zhang, MD
CONTACT
How is the study designed?
Study Type
OBSERVATIONAL
Masking
N/A
Allocation
N/A
Model
N/A
Primary Purpose
N/A
Number of Arms
0
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here